TransMedics Group (HAM:8T8) Valuation Rank


HAM:8T8 TransMedics Group Inc HAM:8T8
69 GF Score
Price €60.02
GF Value €162.08
! 9 Warning Signs
View Full Analysis

What is TransMedics Group Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

TransMedics Group Valuation Rank Related Terms

HAM:8T8
69GF Score
TransMedics Group Inc HAM:8T8
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is TransMedics Group (HAM:8T8) Overvalued in 2026?

Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued. The current stock price of €60.02 is trading 63% below its estimated GF Value™ of €162.08.

Key valuation signals for HAM:8T8:

  • Valuation Rank:
  • GF Value™: €162.08 vs. price of €60.02 (63% below fair value)
  • GF Score™: 69/100 with 9 warning signs

No single metric tells the full story. See the HAM:8T8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TransMedics Group Business Description

Address 200 Minuteman Road, Andover, MA, USA, 01810
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
69GF Score

Get the complete analysis for HAM:8T8

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€60.02
Price
€162.08
GF Value